FREE patent keyword monitoring and additional FREE benefits. http://images1.freshpatents.com/images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents

Interleukin

Interleukin patent applications listed include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.

Related Categories:

Drug, Bio-affecting And Body Treating Compositions


Lymphokine > Interleukin



Bioactive compositions derivable from platelet concentrates, and methods for preparing and using same
03/05/15 - 20150064133 - The present disclosure provides a composition comprising a bioactive fraction derived from a platelet concentrate, methods of making the bioactive fraction, and culture medium supplemented with the bioactive fraction. Preferred bioactive fractions have relatively low fibrinogen concentrations while retaining native growth factors in beneficial amounts and ratios....

Chemically induced intracellular hyperthermia
02/26/15 - 20150056160 - An invention relating to therapeutic pharmacological agents and methods to chemically induce intracellular hyperthermia and/or free radicals for the diagnosis and treatment of infections, malignancy and other medical conditions. The invention relates to a process and composition for the diagnosis or killing of cancer cells and inactivation of susceptible bacterial,...

Regeneration of endogenous myocardial tissue
02/26/15 - 20150056161 - This invention provides a method of treating a disorder of a subject's heart involving loss of cardiomyocytes which comprises administering to the subject a composition comprising an amount of a human stromal derived factor-1 and an amount of a human granulocyte-colony stimulating factor, the composition being administered in an amount...

Therapeutic il-13 polypeptides
02/26/15 - 20150056162 - Variant IL-13 polypeptides are provided, which are engineered to have one or more of the following properties: (a) altered affinity for IL-13Rα2, relative to the native human IL-13 protein; (b) altered affinity for IL-13Rα1 relative to the native human IL-13 protein; (c) a disruption in the binding site for IL-4Rα...

Leukotoxin e/d as a new anti-inflammatory agent and microbicide
02/26/15 - 20150056163 - The present invention relates to methods for preventing or treating Human Immunodeficiency Virus (HIV) infection, inflammatory conditions, and graft-versus-host-disease (GVHD) in a subject. Therapeutic compositions of the present invention comprise Leukocidin E (LukE) and/or D proteins or polypeptides. The invention further relates to methods of treating Staphylococcus aureus infection by...

New anti-mycobacterial drugs against tuberculosis
02/19/15 - 20150050237 - The present invention relates to the field of anti-mycobacterial therapeutics, in particular the treatment of tuberculosis, especially including pulmonary multidrug-resistant tuberculosis (MDR-TB), with applications in extensively drug-resistant tuberculosis (XDR-TB) and extremely drug-resistant tuberculosis (XXDR-TB), preferably in combination therapy....

Treatment of osteoarthritis and pain
02/19/15 - 20150050238 - The present invention relates to the treatment of osteoarthritis and pain using IL-1α and IL-1β binding proteins, including anti-IL-1α and anti-IL-1β antibodies and engineered multivalent and multispecific IL-1α and IL-1β binding proteins....

Methods of treating autoimmune diseases
02/12/15 - 20150044164 - Novel methods for treating patients with autoimmune diseases are disclosed. The methods of the invention include first depleting circulating lymphocytes in the mammal, e.g., by administering anti-thymocyte antibody, and then, during the course of repopulation, administering to the mammal a therapeutically effective amount of latent TGF-β and/or another agent that...

Costimulatory b7-h1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target
02/12/15 - 20150044165 - The invention features methods of diagnosis by assessing B7-H1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with B7-H1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression...

Compositions and methods for treatment of exercise-induced pulmonary hemorrhage or nasopharyngeal cicatrix
02/12/15 - 20150044166 - Methods, compositions, and medical device systems relating to treating exercise-induced pulmonary hemorrhage (EIPH) and nasopharyngeal cicatrix (NC) in a mammal. For example, one method comprises administering through inhalation a composition comprising a physiologically acceptable carrier and an effective amount of each of one or more stem cell derived factors. Exemplary...

Methods of reducing salmonella in poultry
02/05/15 - 20150037277 - Described herein are methods of reducing Salmonella in the intestines of poultry in need thereof by administering to a poultry bird an effective amount of an interleukin-10 peptide or an isolated antibody that specifically binds an interleukin-10 peptide. Administering may be performed within 1 to 4 weeks of harvest of...

Initial relative lymphocyte count as predictive biomarker
02/05/15 - 20150037278 - The invention relates to a method for predicting an improved therapeutic benefit for an individual with a tumor load before initiating an immune therapy which is capable of activating immune cells against said tumor as well as to pharmaceutical compositions for use in this method....

Sustained release formulation of interleukin-10 for wound treatment and related methods
02/05/15 - 20150037279 - A sustained release formulation of interleukin-10 for wound treatment and related methods is provided....

Methods of treating or preventing viral diseases by blocking interleukin-21
01/29/15 - 20150030562 - The invention provides a method of treating or preventing viral diseases in a mammal comprising administering to the mammal an interleukin (IL)-21 blocking agent in an amount effective to treat or prevent the viral disease in the mammal. Also provided is a method of reducing the activation or recruitment of...

Skin cream
01/22/15 - 20150023908 - The present invention relates to skin care compositions, including cosmeceuticals, for topical application, and more particularly, a skin cream, comprising exosomes and cell culture medium conditioned by cells grown in two-dimensional culture. Also included are methods of making and using such compositions and kits comprising the skin cream therein....

Lymph node-targeting nanoparticles
01/22/15 - 20150023909 - Provided are nanoparticles comprising heparin, chitosan, and at least one immunomodulatory agent, e.g. a cytokine. The cytokine can be selected from the group consisting of TNF, IL-12, IL-2, IL-23, IL-1α, IL-10, IL-18, and combinations thereof. Further provided are methods of making a nanoparticle comprising mixing a first composition comprising heparin...

Granulysin in immunotherapy
01/22/15 - 20150023910 - Methods of stimulating or enhancing an immune response in a host are disclosed. The methods include contacting a monocyte with 15 kD granulysin thereby producing a monocyte-derived dendritic cell. In one example, the method further includes contacting the monocyte or monocyte-derived dendritic cell with a target antigen, such as a...

Device-based methods for localized delivery of cell-free carriers with stress-induced cellular factors
01/22/15 - 20150023911 - The present invention relates to an in vitro or ex vivo method of preparing a cell-free composition, said method comprising or consisting of (a) subjecting cells to stress; and (b) collecting factors produced, preferably secreted by said cells when subjected to said stress, thereby obtaining said cell-free composition; wherein said...

Combinations of albumin-based drug delivery systems
01/22/15 - 20150023912 - The present invention relates to a composition comprising at least two different albumin-based drug delivery systems, as well as to a pharmaceutical composition comprising said composition....

Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
01/15/15 - 20150017120 - The present invention provides a method of enhancing adoptive cell therapy (ACT) by administering an extended-pharmacokinetic (PK) interleukin (IL)-2 to a cancer subject receiving ACT, optionally in combination with a therapeutic antibody. Methods of treating cancer and promoting tumor regression are also provided....

Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
01/15/15 - 20150017121 - The invention relates to a combination medicament for treatment of malignant neoplastic disease. The combination medicament comprises an IL-12 polypeptide having a biological activity of IL-12 or a nucleic acid expression vector comprising a sequence encoding such IL-12 polypeptide, and a non-agonist CTLA-4 ligand or non-agonist PD-1 ligand, particularly an...

Conditioned medium obtained from placental mesenchymal stem cells and use thereof in the therapeutic treatment of preeclampsia
01/15/15 - 20150017122 - It is described a conditioned medium (CM) obtainable by culturing, in a liquid culture medium, placental mesenchymal stem cells isolated from the placental tissue of pregnant women not affected by preeclampsia. The conditioned medium of the invention includes at least IL-6, IL-10 and MCP-1 proteins and it is effective for...

Il-1 family variants
01/15/15 - 20150017123 - The present invention provides compositions and methods relating to IL-1Rrp2 requiring proteins....

Method for the production of an immunostimulating mucin (muc1)
01/08/15 - 20150010495 - The present invention relates to a method for producing or identifying a MUC1 molecule which is able to generate an immune response in humans. The invention also relates to a method for producing or identifying a cell, cell lines or cell lysates containing a MUC1 molecule that is able to...

Inkt cell modulators and methods of using the same
01/08/15 - 20150010496 - Disclosed herein are α-galactosylceramide (α-GalCer) analogs and compositions thereof, methods of activating invariant Natural Killer T (iNKT) cells using said analogs, methods of treating diseases by activating iNKT cells using said analogs, and combination therapy of said analogs....

Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins c3a/c4a, and chemotactic factors
01/08/15 - 20150010497 - The present invention refers to a combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins C3a/C4a, and chemotactic factors. The invention also relates to a process for the preparation of said combination from serum, placenta or colostrum and to composition containing said combination for use in...

Immunocytokines for cancer treatment in combination with chemotherapeutic agents
01/08/15 - 20150010498 - This invention relates to the treatment of cancer using anti-cancer agents, such as doxorubicin or paclitaxel, in combination with antibody-interleukin 2 (IL2) conjugates which target tenascin-C....

Insulin-mimetics as therapeutic adjuncts for bone regeneration
01/08/15 - 20150010499 - Methods of promoting bone healing or regeneration by locally administering insulin mimetic agents to patients in need thereof and new uses of insulin-mimetic compounds for accelerating bone-healing processes are disclosed. Bone injury treatment and void filler devices, products and kit suitable for local administration of insulin-mimetic agents or compositions thereof...

Homogeneous preparations of il-31
01/08/15 - 20150010500 - Homogeneous preparations of human and murine IL-31 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity....

Intervertebral disc repair compositions and methods
01/08/15 - 20150010501 - The present invention provides compositions, methods and devices for treatment of degenerative disc disease or the repair of a disc in need of repair. The composition or the formulation includes freshly isolated or culture expanded ELA cells, which can be cyropreserved. The composition or a formulation also includes in various...

Radiation protection device and methods thereof
01/01/15 - 20150004131 - A radiation protection device for providing protection of a body part that includes active bone marrow from ionizing radiation may include a radiation protection component configured to be placed adjacent to and externally cover the body part so as to reduce a radiation dose absorbed in that body part....

Compositions and methods for generating an immune response
01/01/15 - 20150004132 - We have developed DNA and viral vectors that can be used, alone or in combination, as a vaccine against one HIV clade, subtype, or recombinant form of HIV or against multiple HIV clades, subtypes, or recombinant forms. Moreover, the vectors can encode a variety of antigens, which may be obtained...

Compositions and methods for treating steatohepatitis, liver fibrosis, and hepatocellular carcinoma (hcc)
01/01/15 - 20150004133 - The invention provides methods and compositions for reducing symptoms of steatohepatitis and/or liver fibrosis and/or hepatocellular carcinoma (HCC) in a mammalian subject in need thereof, comprising administering to the mammalian subject a therapeutic amount of a compound that reduces the level of interleukin 17 (IL-17) and/or interleukin 23 (IL-23) and/or...

Compositions for preventing cardiac arrhythmia
12/25/14 - 20140377217 - Disclosed herein are compositions and methods for treating or preventing a cardiac arrhythmia in a subject....

Hcv immunotherapy
12/25/14 - 20140377218 - The invention relates to the use of Interleukin-7 (IL-7), for treating hepatitis C in a patient infected with hepatitis C virus, wherein said patient has been treated or is being treated with an antiviral agent or a combination of antiviral agents that reduces viral load....

Hiv inhibitors
12/25/14 - 20140377219 - Chemical compounds that inhibit retroviruses are presented herein. More particularly, this disclosure provides small molecule compounds that inhibit infection with, or treat infection caused by, human immunodeficiency viruses....

Gene expression signatures for staging and prognosis of prostate, breast and leukemia cancers
12/25/14 - 20140377220 - The present invention is drawn to methods of assessing and treating cancers such as ERG-related, prostate, breast and leukemia, by examining the expression of combinations of particular genes disregulated in this disease state. The combinations of genes are selected from the following genes: inhibitor of growth family, member 3 (HSTG3);...

Biomarkers and combination therapies using oncolytic virus and immunomodulation
12/25/14 - 20140377221 - The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer....

Use of interleukin-22 in the treatment of fatty liver disease
12/25/14 - 20140377222 - The present invention relates to use of interleukin-22 (IL-22) for treating fatty liver disease by decreasing the levels of transaminases. The use of IL-22 in decreasing the levels of transaminases is also provided....

Methods for autologous stem cell transplantation
12/18/14 - 20140369955 - Materials and methods for obtaining populations of lymphocytes and administering the population of lymphocytes to a subject are disclosed herein. In particular, disclosed herein are materials and methods for obtaining lymphocyte populations that contain at least about 0.5×109 NK cells per kilogram weight of the subject from which the cells...

Conjugates of gm-csf and il-7, compositions and methods related thereto
12/18/14 - 20140369956 - In certain embodiments, this disclosure relates to conjugates comprising GM-CSF and IL-7 and uses related thereto, e.g., enhancing the adaptive immune system. Typically the GM-CSF and IL-7 are connected by a polymer linker, e.g., polypeptide. In certain embodiments, the disclosure relates to nucleic acids encoding these polypeptide conjugates, vectors comprising...

Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins c3a/c4a, immunoglobulins and chemotactic factors
12/18/14 - 20140369957 - The present invention refers to a combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins C3a/C4a, immunoglobulins and chemotactic factors. The invention also relates to a process for the preparation of said combination from serum, placenta or colostrum and to composition containing said combination for use...

Il-12 for radiation protection and radiation-induced toxicity mitigation
12/18/14 - 20140369958 - Aspects and embodiments of the instant disclosure provide therapeutic methods and compositions comprising inter-leukin 12 (IL-12) useful for treating radiation-induced damage in a subject. In particular, the instant disclosure provides methods and compositions for radiation protection and/or radiation toxicity mitigation for the treatment of acute radiation syndrome and radiation induced...

Formulation having mobilizing activity
12/11/14 - 20140363394 - The present innovation relates to a novel formulation capable of increasing the amount of stem cells and progenitor cells in circulation in the peripheral blood of a mammal; the formulation is characterized in that it contains defibrotide in combination with at least one haematopoietic factor having the capacity to mobilize...

Adoptive cell therapy with specific regulatory lymphocytes
12/04/14 - 20140356318 - The present invention comprises a method of treatment of an autoimmune disease involving a specific tolerance induction (“STI”) event, wherein the method includes: collecting a first sample from the patient prior to the STI event; detecting an STI event or performing a procedure that correlates in time to an STI...

Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases
12/04/14 - 20140356319 - The present invention describes peptides comprising phycocyanobilin (PCB), as well as the medical use of said peptides and that of PCB, due to the neuroprotector and/or neuroregenerative effects identified for them. Furthermore, pharmaceutical combinations of said peptides and of PCB with proteins or other peptides with synergic effect justify their...

Polyoma virus jc peptides and proteins in vaccination and diagnostic applications
12/04/14 - 20140356320 - The present invention relates to the field of vaccination or immunization, in particular therapeutic vaccination, and diagnosis. Pharmaceutical compositions and kits capable of eliciting a protective immune response against polyoma virus JC (JCV) are disclosed, which may be used e.g., for therapy or for prevention of progressive multifocal leukoencephalopathy (PML)...

Materials and methods for treatment of liver cancer
12/04/14 - 20140356321 - Granulin-epithelin precursor (GEP), a pluripotent growth factor, is a hepatic oncofetal protein defining a cancer stem cell (CSC) population in liver cancer. The present invention provides the use of GEP inhibitors (including anti-GEP antibody) for inhibiting immune evasion by liver cancer cells and for eliminating liver cancer stem cells....

Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
12/04/14 - 20140356322 - The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins that are degraded and/or otherwise inhibited by bifunctional compounds of the present invention. In particular, the present invention is directed to compounds, which contain on...

Compositions and methods for soft tissue augmentation
12/04/14 - 20140356323 - The present invention provides compositions comprising isolated human collagen, isolated human elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation....

Method of enhanced antibiotic activity via chemotaxis
11/27/14 - 20140348780 - Compositions and methods for treating infectious diseases produced by biofilms are disclosed. More specifically, the present disclosure refers to a pharmaceutical compositions which may be used for treating biofilm infections, specifically, biofilms formed by bacteria such as Pseudomonas, E. coli, Klebsiella, and other human pathogens. Pharmaceutical compositions may include a...

Conjugates of gm-csf and il-9, compositions and methods related thereto
11/27/14 - 20140348781 - In certain embodiments, this disclosure relates to conjugates comprising GM-CSF and IL-9 and uses related thereto, e.g., enhancing the adaptive immune system. Typically the GM-CSF and IL-9 are connected by a polymer linker, e.g., polypeptide. In certain embodiments, the disclosure relates to nucleic acids encoding these polypeptide conjugates, vectors comprising...

Vaccine immunotherapy for immune suppressed patients
11/27/14 - 20140348782 - A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naive T-cells and restoring T-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naive T-cells and exposing the naive T-cells to endogenous or exogenous antigens at an appropriate site....

Vaccine immunotherapy for immune suppressed patients
11/27/14 - 20140348783 - A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naive T-cells and restoring T-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naive T-cells and exposing the naive T-cells to endogenous or exogenous antigens at an appropriate site....

Compositions and methods for treatment of angiogenesis in pathological lesions
11/27/14 - 20140348784 - Treatment of lesions of pathological angiogenesis, especially tumors, rheumatoid arthritis, diabetic retinopathy, age-related muscular degeneration, and angiomas. A conjugate is used comprising a molecule that exerts a biocidal or cytotoxic effect on target cells in the lesions and an antibody directed against an extracellular matrix component which is present in...

Neutralizing gp41 antibodies and their use
11/27/14 - 20140348785 - Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies...

Beta-mannosylceramide and stimulation of nkt cell anti-tumor immunity
11/27/14 - 20140348786 - β-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of α-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising β-mannosylceramide, as...

Purified proteins
11/20/14 - 20140341843 - The present invention provides methods and compositions for the preparation and delivery of chimeric cytokine proteins, including cell cultures, methods of purification and purified compositions....

Immunocytokines in combination with anti-erbb antibodies for the treatment of cancer
11/20/14 - 20140341844 - This invention relates to the treatment of cancer using anti-ErbB antibodies, such as cetuximab or trastuzumab, in combination with antibody-interleukin 2 (IL2) conjugates which target tenascin-C....

Methods and systems for treating cell proliferation related disorders
11/20/14 - 20140341845 - and a kit for performing the method, a computer implemented system for performing the method, a pharmaceutical composition useful in the method and a method for causing an autovaccine effect in a subject using the method....

Methods of inhibiting photoreceptor apoptosis
11/20/14 - 20140341846 - The present invention provides methods to prevent photoreceptor death. In particular, the present invention provides peptides which prevent FAS-mediated photoreceptor apoptosis....

Drug delivery product and methods
11/13/14 - 20140335047 - The present invention provides a particulate delivery system comprising an extracted yeast cell wall comprising beta-glucan, a payload molecule and a payload trapping molecule. The invention further provides methods of making and methods of using the particulate delivery system....

7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of using the same in combination therapy
11/13/14 - 20140335048 - or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent are administered either simultaneously or sequentially....

Quil a fraction with low toxicity and use thereof
11/13/14 - 20140335049 - Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens. Other adjuvants can comprise...

Conjugates of an il-2 moiety and a polymer
11/06/14 - 20140328791 - Conjugates of an IL-2 moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the nonpeptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, methods of administering compositions to an individual, nucleic acid sequences, expression...

Methods and compositions for treating and preventing viral infections
11/06/14 - 20140328792 - A method of treating or preventing a systemic viral infection in a mammal by administering a pharmaceutically acceptable composition selected from the group consisting of squalamine, an active isomer thereof, and an active analogue thereof, via a dosing regimen that delivers effective antiviral concentrations of squalamine. Also compositions for achieving...

Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
11/06/14 - 20140328793 - Compounds, compositions, and methods of treatment and prevention of HIV infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the...

Anti-il-6 vaccine composition
10/30/14 - 20140322161 - The present invention relates to a pharmaceutical composition comprising, by way of active ingredient, at least one polypeptide comprising, or constituted by a sequence constituted by at least 8 contiguous amino acids and from at the most 30 contiguous amino acids chosen from within the interleukin-6 sequence and from at...

Use of ferritin to treat iron disorders
10/30/14 - 20140322162 - Methods and compositions for treating an iron disorder in a patient are presented, including methods for orally administering a recombinant yeast that produces H-ferritin-iron complex or the H-ferritin-iron complex extracted from the yeast. Data indicate that administration of the recombinant yeast more effectively increases hemoglobin, hematocrit and transferrin saturation than...

Neutralizing antibodies to hiv-1 and their use
10/30/14 - 20140322163 - Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic...

Il-2 derivatives polypeptides with agonist activity for therapy of cancer and chronic infections
10/23/14 - 20140314709 - The present invention relates to polypeptides which share primary sequence with human IL-2, except for several amino acids that have been mutated. The mutations introduced substantially reduce the ability of these polypeptides to stimulate in vitro and in vivo regulatory T cells (T CD4+CD25+FoxP3+) and make them more effective in...

Il-12 p40 monomer, monoclonal antibody against p40 homodimer and the combination of the two for autoimmune disease treatment
10/23/14 - 20140314710 - A novel approach to discover new drugs against MS and other autoimmune diseases is disclosed. The p40 family of cytokines has four members which include interleukin-12 (IL-12), the p40 monomer (p40), the p40 homodimer (p402), and the IL-23. To facilitate the studies on p402 and p40, neutralizing monoclonal antibodies (mAb)...

Il-22 polypeptides and il-22 fc fusion proteins and methods of use
10/23/14 - 20140314711 - The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof....

Fusion protein comprising an interleukin 4 and interleukin
10/23/14 - 20140314712 - The invention is concerned with a fusion protein comprising interleukin 10 and interleukin 4, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing...